Valneva Aktie

2,41 EUR +0,04 EUR +1,47 %

13:01:51

STU

2,21 CHF -0,02 CHF -0,81 %

13:00:49

BRX

Valneva jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.435,74 Mio. EUR

Div. Rendite0,00%

WKNA0MVJZ

ISINFR0004056851

SymbolINRLF

Valneva Aktien News

Sortieren:Datum Meistgelesen

21.10.24GlobeNewswireValneva to Present on Chikungunya at Several Leading Scientific Conferences

16.10.24GlobeNewswireValneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

10.10.24GlobeNewswireValneva Hosts Investor Day in New York City

04.10.24GlobeNewswireValneva SE - Declaration of shares and voting rights - September 30, 2024

03.10.24GlobeNewswireValneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

18.09.24GlobeNewswireValneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

13.09.24GlobeNewswireValneva Announces the Success of its Private Placement Raising approximately €60 Million

12.09.24GlobeNewswireValneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

04.09.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: August 31, 2024

03.09.24GlobeNewswireValneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

13.08.24GlobeNewswireValneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

06.08.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: July 31, 2024

01.08.24GlobeNewswireValneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

22.07.24GlobeNewswireCEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

17.07.24GlobeNewswirePhase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

04.07.24GlobeNewswireDeclaration of shares and voting rights - Valneva SE - June 30, 2024

01.07.24GlobeNewswireValneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

26.06.24GlobeNewswireValneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

24.06.24GlobeNewswireValneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

05.06.24GlobeNewswireValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

04.06.24GlobeNewswireVALNEVA - Declaration of shares and voting rights: May 31, 2024

04.06.24GlobeNewswireValneva to Present and Hold Investor Meetings at Upcoming Conferences in June

03.06.24GlobeNewswireValneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

31.05.24GlobeNewswireValneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

21.05.24GlobeNewswireValneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

13.05.24GlobeNewswireValneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

07.05.24GlobeNewswireValneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

06.05.24GlobeNewswireDeclaration of shares and voting rights April 30, 2024 - VALNEVA SE

04.04.24GlobeNewswireDeclaration of voting rights - Valneva SE, March 2024

26.03.24GlobeNewswireValneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

25.03.24GlobeNewswireValneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

21.03.24GlobeNewswireValneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

20.03.24GlobeNewswireValneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

18.03.24GlobeNewswireValneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

06.03.24GlobeNewswireVALNEVA Declaration of shares and voting rights - February 29, 2024

04.03.24GlobeNewswireValneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

29.02.24GlobeNewswireU.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

15.02.24GlobeNewswireValneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

07.02.24GlobeNewswireVALNEVA: Declaration of shares and voting rights - January 31, 2024

05.02.24GlobeNewswireValneva Announces Sale of Priority Review Voucher for $103 Million

Valneva News

Valneva News: auf dieser Seite finden Sie alle Valneva News und Nachrichten zur Valneva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Valneva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Valneva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.